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Abstract
Background: AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is the second most frequent
cancer associated with AIDS, and is a frequent cause of death in HIV-infected individuals.
Experimental analysis of AIDS-NHL has been facilitated by the availability of an excellent animal
model, i.e., simian Acquired Immunodeficiency Syndrome (SAIDS) in the rhesus macaque
consequent to infection with simian immunodeficiency virus. A recent study of SAIDS-NHL
demonstrated a lymphoma-derived cell line to be sensitive to the growth inhibitory effects of the
ubiquitous cytokine, transforming growth factor-beta (TGF-beta). The authors concluded that
TGF-beta acts as a negative growth regulator of the lymphoma-derived cell line and, potentially, as
an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis. The present study
was conducted to assess whether other SAIDS-NHL and AIDS-NHL cell lines are similarly sensitive
to the growth inhibitory effects of TGF-beta, and to test the hypothesis that interleukin-6 (IL-6)
may represent a counteracting positive influence in their growth regulation.
Methods: Growth stimulation or inhibition in response to cytokine treatment was quantified using
trypan blue exclusion or colorimetric MTT assay. Intracellular flow cytometry was used to analyze
the activation of signaling pathways and to examine the expression of anti-apoptotic proteins and
distinguishing hallmarks of AIDS-NHL subclass. Apoptosis was quantified by flow cytometric
analysis of cell populations with sub-G1 DNA content and by measuring activated caspase-3.
Results: Results confirmed the sensitivity of LCL8664, an immunoblastic SAIDS-NHL cell line, to
TGF-beta1-mediated growth inhibition, and further demonstrated the partial rescue by
simultaneous treatment with IL-6. IL-6 was shown to activate STAT3, even in the presence of TGF-
beta1, and thereby to activate proliferative and anti-apoptotic pathways. By comparison, human
AIDS-NHL cell lines differed in their responsiveness to TGF-beta1 and IL-6. Analysis of a recently
derived AIDS-NHL cell line, UMCL01-101, indicated that it represents immunoblastic AIDS-
DLCBL. Like LCL-8664, UMCL01-101 was sensitive to TGF-beta1-mediated inhibition, rescued
partially by IL-6, and demonstrated rapid STAT3 activation following IL-6 treatment even in the
presence of TGF-beta1.
Conclusion: These studies indicate that the sensitivity of immunoblastic AIDS- or SAIDS-DLBCL
to TGF-beta1-mediated growth inhibition may be overcome through the stimulation of
proliferative and anti-apoptotic signals by IL-6, particularly through the rapid activation of STAT3.
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Background
AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is
the second most frequent cancer (following Kaposi's sar-
coma) associated with AIDS, and is the cause of death in
approximately 16% of HIV-infected individuals [1,2]. The
lymphoma typically represents a clonal expansion of B-
cell origin classified as high grade Burkitt lymphoma (BL)
or diffuse large B-cell lymphoma (DLBCL) with centrob-
lastic or immunoblastic features [3]. Epstein-Barr virus
(EBV) infection of tumor cells is a frequent characteristic,
occurring in 30% of AIDS-BL and up to 90% of AIDS-
DLBCL depending on the histological subtype. Genetic
lesions in c-myc, bcl-6 and/or p53 have also been impli-
cated in some histologic subtypes of AIDS-NHL [4]. The
lymphoma tends to occur as a late complication of AIDS
in long-term survivors of the disease. Thus, as life expect-
ancy of HIV-infected individuals has been prolonged by
highly active antiretroviral therapy (HAART), it might be
anticipated that the incidence of AIDS-NHL would
increase. Indeed, recent reports differ as to the impact of
HAART on the incidence of systemic AIDS-NHL, although
improved response to standard therapy and increased sur-
vival have been widely reported [3,5]. Experimental anal-
ysis of AIDS-NHL pathogenesis has been facilitated by the
availability of an excellent animal model for human
AIDS, i.e., Simian Acquired Immunodeficiency Syndrome
(SAIDS) in the rhesus macaque (Macaca mulatta) conse-
quent to infection with simian immunodeficiency virus
(SIV). SAIDS-related non-Hodgkin's lymphoma (SAIDS-
NHL) occurs in the SIV-infected rhesus macaque with an
incidence approximating human AIDS-NHL [6,7]. The
lymphoma typically represents a clonal expansion of B-
cell origin classified as DLBCL with immunoblastic fea-
tures or, less frequently, as Burkitt's-like lymphoma [8].
Most cases of SAIDS-NHL are infected with rhesus lym-
phocryptovirus (RhLCV), a homologue of Epstein-Barr
virus [9]. The tumors are widely disseminated in anatomic
distribution involving extranodal sites, most frequently
the gastrointestinal tract, the genitourinary tract and the
heart [6,7].
Analysis of the disease in humans or simians implicates
cytokine dysregulation as a fundamental influence in
pathogenesis [10-12]. A role for interleukin-6 (IL-6), in
particular, is supported by a large body of evidence [11-
14]. IL-6 is a stimulator of B-cell proliferation and differ-
entiation that is expressed in EBV-positive AIDS-BL and to
high levels in AIDS-DLBCL of both centroblastic and
immunoblastic types. Evidence indicates that the cytokine
may be expressed from the tumor cells themselves or from
tumor-infiltrating cells [11,13,15-17]. Tumor cells fre-
quently express the receptor for IL-6, thus rendering them
responsive to autocrine and/or paracrine IL-6-mediated
stimulation [13,16]. The secretion of IL-6 is further signif-
icant in AIDS-NHL because it may render the tumor cells
resistant to the cytotoxic effects of chemotherapeutic
drugs and/or increase the side effects [10,18,19]. Growth
inhibitory effects of cytokines have been implicated as
well. In particular, a recent study using a SAIDS-NHL-
derived cell line demonstrated the growth inhibitory
effects of the ubiquitous cytokine, transforming growth
factor-β (TGF-β). TGF-β was shown to reduce cell viability
by 67% and to increase apoptosis by 69% (range, 33–
111%). The authors concluded that TGF-β acts as a nega-
tive growth regulator of the lymphoma-derived cell line
and, potentially, as an inhibitory factor in the regulatory
network of AIDS-related lymphomagenesis [20]. These
findings were unexpected, given that (1) many cancers,
including leukemias and other tumors of hematopoietic
origin, typically develop resistance to TGF-β as a mecha-
nism for progression [21-23], and (2) the majority of
SAIDS-related lymphomas are infected with RhLCV,
whose human-specific counterpart, EBV, is known to
impart resistance to TGF-β inhibition in human lymphob-
lastoid cell lines [24,25]. Indeed, the marked sensitivity to
growth inhibition by TGF-β suggests that a counteracting
positive influence may be operative in SAIDS-NHL.
The present study was conducted to assess whether other
SAIDS-NHL and AIDS-NHL cell lines are similarly sensi-
tive to the growth inhibitory effects of TGF-β, and to test
the hypothesis that IL-6 may represent a counteracting
positive influence in their growth regulation. The latter
hypothesis was considered to be a reasonable possibility
since IL-6 signaling is known to activate proliferative and
survival pathways in target cells, including those mediated
by signal transducer and activator of transcription-3
(STAT3), extracellular signal-regulated kinase 1/2 (ERK1/
2), and the bcl-2 family of apoptotic regulators [26-28].
Further, a recent report using a cultured hepatoma cell
line showed that IL-6 counteracted the growth inhibitory
influence of TGF-β1, primarily through the activation of
multiple anti-apoptotic signaling pathways [29]. The
present results show that some lymphoma-derived cell
lines of human and simian origin are sensitive to TGF-β-
mediated growth inhibition, and that IL-6 signaling
through multiple pathways moderates that inhibition.
The results demonstrate the multiple mechanisms
involved in the interaction between TGF-β and IL-6 sign-
aling in AIDS- or SAIDS-NHL cell lines, and suggest a bal-
ance between positive and negative growth regulatory
influences in this disease.
Methods
Cultured Cell lines and Reagents
LCL8664, originally derived from a case of SAIDS-NHL at
the Tulane National Primate Research Center, was
obtained from American Type Culture Collection (ATCC
CRL-1805). LCL8664 cells were cultured in RPMI-1640
medium with 2 mM GlutaMAX-l, 10% heat-inactivatedBMC Cancer 2007, 7:35 http://www.biomedcentral.com/1471-2407/7/35
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fetal bovine serum (FBS) and 10 µg/ml gentamicin sulfate
(Invitrogen Corporation, Carlsbad, CA). The 2F7, BCBL-1
and UMCL01-101 cell lines were obtained from the AIDS
and Cancer Specimen Resource at the University of Cali-
fornia, San Francisco. 2F7 was maintained in RPMI-1640
medium with 2 mM GlutaMAX-I, 10% heat-inactivated
FBS, 0.05 mM β-mercaptoethanol, 1 mM sodium pyru-
vate, and 10 µg/ml gentamicin. UMCL01-101 and BCBL-
1 were maintained in the same medium as for 2F7 but
without sodium pyruvate. Recombinant human IL-6 pro-
tein was obtained from Biosource International, Inc.
(Camarillo, CA) and recombinant human TGF-β1 was
obtained from R&D Systems, Inc. (Minneapolis, MN).
LY294002 was obtained from Sigma-Aldrich Company
(St. Louis, MO).
DNA isolation and Southern blot analysis
Large molecular weight genomic DNA was isolated from
lymphoma 8664 and from lymphoma-derived cell line
LCL8664, and Southern blot analysis was performed, as
previously described [30]. Organization of the immu-
noglobulin heavy chain (IgH) locus was examined using
the lgHJ6 probe (DAKO Corporation, Carpinteria, CA).
Cell proliferation assays
To quantify cell viability by trypan blue exclusion, live
cells were enumerated after trypan blue staining using
light microscopy. To quantify cell proliferation using the
MIT tetrazolium dye reduction assay, cells were deposited
in triplicate wells of a 96-well flat-bottom tissue culture
plate at 2 × 105 cells per ml (LCL8664), 2.5 × 104 cells per
ml (2F7), 1.75 × 105 cells per ml (BCBL-1) or 1 × 105 cells
per ml (UMCL01-101). At regular intervals after the addi-
tion of cytokines, 10 µl of MTT reagent (R&D Systems,
Minneapolis, MN) was added per 100 µl culture volume,
and cells were incubated for 4 hours at 37°C. After 4
hours, 100 µl of detergent reagent (R&D Systems, Minne-
apolis, MN) was added to each well followed by incuba-
tion for 3 hours at 37°C. The absorbance at 595 nm (A595)
of each sample well was measured using an automated
plate reader. The entire experiment with each cell line was
repeated at least twice. The results were analyzed statisti-
cally using one-way ANOVA with Bonferroni post-test
with statistical significance considered as p < 0.05.
Intracellular flow cytometry
For time course analyses of response to cytokines, cells
were deposited in culture medium at 1 × 106 – 5 × 106
cells/ml, treated with IL-6 or TGF-β1 as indicated and col-
lected at regular intervals thereafter. For studies involving
a short time course of ≤ 60 minutes, cells were serum-
starved for 24 hours in RPMI-1640 with 0.5% BSA before
the addition of cytokines. Cells were fixed in 1% formal-
dehyde and incubated at room temperature for 10 min-
utes. Fixed cells were permeabilized while vortexing in ice-
cold 90% methanol and incubated at 4°C for 30 minutes.
Permeabilized cells were washed two times in a stain
buffer of phosphate buffered saline (PBS) with 0.5%
bovine serum albumin. For staining, 1 × 105 – 5 × 105 cells
were incubated at room temperature with primary anti-
body for 1 hour and secondary antibody for 1 hour. Sam-
ples were then washed with PBS. Flow cytometry was
performed using a Becton Dickinson FACSCalibur flow
cytometer and interpreted with BD Bioscience CELLQuest
Pro Software. Dead cells were excluded from analysis
based on forward and side scatter pattern. Immunological
reagents were Alexa Fluor 488-conjugated monoclonal
antibodies directed against phosphorylated STAT3
(#557814), phosphorylated ERK1/2 (#612592) and
phosphorylated p38MAPK (#612594), and phycoeryth-
rin-conjugated monoclonal antibody against LMP-1 (#
550018) (BD Biosciences Pharmingen, San Diego, CA);
polyclonal rabbit antibody against phosphorylated Akt
(Cell Signaling Technology, Inc., Danvers, MA; #CS
9271s) with Alexa Fluor 488-conjugated goat anti-rabbit
IgG (Cell Signaling Technology, Inc., Danvers, MA;
#A11070); FITC-conjugated monoclonal antibody
against Bcl-2 (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA; #sc-7382); and monoclonal antibody against Bcl-6
(Chemicon, Temecula, CA; # MAB4618) with Alexa Fluor
488-conjugated goat anti-mouse IgG (Cell Signaling Tech-
nology, Inc., Danvers, MA; #A21121). For analysis of sub-
G1 DNA content, LCL8664 cells were treated with
cytokine as indicated, fixed, permeabilized, and stained
with 20 µg/ml propidium iodide (PI) in PBS containing
3.8 mM sodium citrate and 8 µg/ml RNase A at 37°C for
30 minutes. Cells were analyzed on a Becton Dickinson
FACSCalibur flow cytometer and interpreted using BD
Bioscience CELLQuest Pro Software and ModFit (Verity
Software House Inc.). Each DNA content histogram was
generated from at least 10,000 gated events. The experi-
ment was repeated three times independently.
Assay for Caspase-3 activity
A colorimetric assay for caspase-3 activity (CaspACE Assay
System, Promega Corporation, Madison, WI) was used
according to the manufacturer's instructions. LCL8664
cells were deposited at 1 × 106 cells/ml, treated with
cytokines as indicated for 16 hours or 24 hours, harvested
by centrifugation at 4°C, washed with ice-cold PBS and
resuspended in Cell Lysis Buffer at a concentration of 108
cells/ml. Cells were lysed by repeated freeze-thaw cycles
and incubated on ice for 15 minutes before centrifugation
to collect the supernatant fraction. Caspase assays were
performed in triplicate using 20 – 50 µg of whole cell
lysate in a 100 µl volume in 96-well plates. Some samples
were treated with the broad caspase inhibitor zVAD-fmk
as a negative control. Plates were sealed, incubated at
37°C for 4 hours, and absorbance at 405 nm (A405) was
measured using an automated plate reader. The resultsBMC Cancer 2007, 7:35 http://www.biomedcentral.com/1471-2407/7/35
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were analyzed statistically using one-way ANOVA with
Bonferroni post-test with statistical significance consid-
ered as p < 0.05.
Immunoblot analysis
Whole cell lysates were prepared by resuspending cells in
RIPA buffer (50 mM Tris-HCI, pH 7.4, 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS)
containing 100 µg/ml PMSF (phenylmethylsulfonyl fluo-
ride; USB Corporation, Cleveland, OH), 1 mM sodium
orthovanadate and 20 µg/ml aprotinin (Sigma-Aldrich
Company (St. Louis, MO) on ice for 1 hour. Lysates were
cleared by centrifugation for 15 minutes at 13000 rpm
(4°C). The protein concentration in whole cell lysates was
determined by the Bradford method (Bio-Rad, Hercules,
CA). Protein samples (20 µg) were denatured in a solution
containing 20% v/v glycerol, 1.25 M β-mercaptoethanol,
5% w/v SDS, 250 mM Tris-HCI, pH 6.7, 20% w/v
bromophenol blue, boiled for 3 minutes and chilled on
ice. Proteins were then separated by SDS-PAGE on a 10%
acrylamide gel and transferred to a nitrocellulose mem-
brane. Membranes were blocked from non-specific bind-
ing with 5% nonfat dried milk and PBS containing 0.1%
tween-20 (PBST) for 1 hour at room temperature. Primary
antibodies were directed against Mcl-1 (Santa Cruz Bio-
technology, lnc., Santa Cruz, CA; #sc-819), LMP-1 and
EBNA2 (DAKO Corporation, Carpinteria, CA; #M0897
and #M7004). Immune complexes were detected using
horseradish peroxidase-conjugated secondary antibody
(Southern Biotech, Birmingham, AL) and ECL Western
Blotting Detection Reagents (Amersham Bioscience, Pis-
cataway, NJ). Antibody to β-tubulin was used as a loading
control.
Results
Based on the previous report of sensitivity of a single
SAIDS-NHL-derived cell line to TGF-β1-mediated inhibi-
tion [20], an investigation was initiated to determine
whether the finding could be recapitulated in LCL8664, a
SAIDS-NHL-derived cell line from the Tulane National
Primate Research Center characterized morphologically as
immunoblastoid DLBCL [8]. LCL8664, like the original
tumor, is of B-cell origin and is infected with rhesus lym-
phocryptovirus (RhLCV), the rhesus homologue of
human EBV [7,9]. Consistent with its immunoblastic phe-
notype, LCL8664 cells express the virus-encoded onco-
genes LMP-1 and EBNA-2 [31](Levy et al., unpublished
observations). Southern blot analysis demonstrated iden-
tical immunoglobulin heavy chain gene rearrangements
in LCL8664 and in the original tumor mass, thereby veri-
fying that LCL8664 represents the predominant malig-
nant clone (Figure 1). LCL8664 cells treated with human
TGF-β1 in increasing amounts from 0.01 ng/ml to 20 ng/
ml showed statistically significant inhibition of cell
growth and viability as measured by trypan blue exclu-
sion, beginning at two days of treatment with TGF-β1 at
doses as low as 0.05 ng/ml. The growth-inhibitory effect
on was maximal and indistinguishable at doses between
1.0 ng/ml and 20 ng/ml of TGF-β1 (Figure 2A). These
results were confirmed using an alternative cell viability
assay (MTT; data not shown). The effect of IL-6 on the
growth of LCL8664 cells was then measured when IL-6
was present alone or in combination with TGF-β1. IL-6
significantly stimulated the proliferation of LCL8664 cells
after two days of treatment. When IL-6 and TGF-β1 were
added together, the inhibitory effect of TGF-β1 was mod-
ulated and cell proliferation was significantly rescued as
compared to TGF-β1 alone (Figure 2B). The effect was
blocked by specific antibody to IL-6 (data not shown).
Studies were then performed to determine whether IL-6
modulates the growth-inhibitory influence of TGF-β1 in
LCL8664 cells through effects on cell proliferation, sur-
vival or both. To examine whether IL-6 activates STAT3 in
SAIDS-NHL as it does in other target cells [26], LCL8664
cells were treated with IL-6, TGF-β1 or a combination of
the two cytokines for time periods ranging from 0 to 60
minutes. Intracellular flow cytometry performed at regu-
lar intervals demonstrated the rapid activation of STAT3
within 5 minutes of IL-6 treatment. TGF-β1 treatment
alone had no effect on STAT3 activation, nor did TGF-β1
treatment delay or diminish STAT3 activation when
added together with IL-6. Thus, IL-6 activates the STAT3
pathway even in the presence of TGF-β1 (Figure 3). As IL-
6 signaling also activates the primarily mitogenic Ras/Raf/
ERK mitogen-activated protein kinase (MAPK) signaling
pathway [26,28], similar intracellular flow cytometric
analysis was performed to examine whether IL-6 activates
this pathway in SAIDS-NHL. The results demonstrated
rapid ERK1/2 phosphorylation within 5 minutes of IL-6
treatment, and ERK1/2 activation persisted for at least 60
minutes. TGF-β1 treatment alone had little or no effect on
ERK1/2 activation, but the addition of TGF-β1 treatment
blunted the activating effect of IL-6. Specifically, when
both IL-6 and TGF-β1 were added together, ERK1/2 acti-
vation was observed with similar timing as with IL-6 alone
but to a diminished extent. Thus, the presence of TGF-β1
reduces but does not block ERK1/2 activation in response
to IL-6 (Figure 3). In contrast, p38MAPK was not activated
in LCL8664 cells by any treatment tested (data not
shown), consistent with the known activation of
p38MAPK by environmental stress rather than by
cytokine stimulation [10].
Since TGF-β induces apoptosis in several cell types [32-34]
while the activation of STAT3 by IL-6 exerts a survival
influence on target cells [27,28], the possibility was next
considered that IL-6 signaling might rescue TGF-β1-medi-
ated inhibition through an anti-apoptotic effect. LCL8664
cells treated with TGF-β1, IL-6 or a combination of theBMC Cancer 2007, 7:35 http://www.biomedcentral.com/1471-2407/7/35
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(A). Dose-dependent growth inhibition of LCL8664 cells by  TGF-β1 Figure 2
(A). Dose-dependent growth inhibition of LCL8664 cells by 
TGF-β1. LCL8664 cells were cultured with TGF-β1 in vary-
ing concentrations from 0 ng/ml to 20 ng/ml. Viable cell 
counts were determined by trypan blue exclusion at regular 
intervals for 8 days. (B). Positive and negative growth regula-
tion of LCL8664 cells by TGF-β1 and IL-6. LCL8664 cells 
were cultured with TGF-β1 (1 ng/ml), IL-6 (20 ng/ml), both, 
or were untreated (untr). Cell viability was quantified over 6 
days of treatment using a tetrazolium dye reduction assay.
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Southern blot analysis of the immunoglobulin heavy chain  (IgH) locus in DNA from (A) LCL8664 cell line and (B) the  original tumor mass from which LCL8664 cell line was  derived Figure 1
Southern blot analysis of the immunoglobulin heavy chain 
(IgH) locus in DNA from (A) LCL8664 cell line and (B) the 
original tumor mass from which LCL8664 cell line was 
derived. DNA (5 µg) was digested with Sacl and hybridized 
to a probe from the human IgH locus, 3' to the JH region. The 
arrows indicate the fragments generated from the locus in 
germline organization. The asterisks indicate the clonal rear-
rangement of the IgH locus. DNA from the tumor mass con-
tains a large germline fragment not present in the cell line, 
indicative of contamination of the original necropsy sample 
with non-neoplastic tissue.
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two cytokines for 24 hours were analyzed by flow cytom-
etry to determine the proportion having a sub-G1 DNA
content. In one representative analysis, the percentage of
cells with sub-G1 DNA content increased from 5% in
untreated cells to 12.5% after TGF-β1 treatment. Treat-
ment of cells with both IL-6 and TGF-β1 decreased the
percentage of cells with sub-G1 DNA content to 6.7%,
thus indicating a partial protective effect of IL-6 even in
the presence of TGF-β1. The induction of apoptosis fol-
lowing TGF-β1 treatment was further analyzed by measur-
ing the expression of cleaved (active) caspase-3, an early
event in the induction of programmed cell death.
LCL8664 cells were treated with TGF-β1, IL-6 or a combi-
nation of both, and caspase-3 activity was quantified
using a colorimetric assay at 16 hours and 24 hours there-
after. Consistent with the analysis of sub-G1 DNA con-
tent, significantly increased caspase-3 activity was evident
by 16 hours of TGF-β1 treatment. A modest but statisti-
cally significant decrease in TGF-β1-induced caspase 3
activity was observed in the presence of IL-6 at 16 hours of
treatment, but was no longer detectable after 24 hours
(Figure 4).
The anti-apoptotic signal stimulated by IL-6 is mediated
ultimately through upregulated expression of Bcl-2 or its
family members, Mcl-1 or Bcl-XL [27]. Intracellular flow
cytometric analysis of LCL8664 cells treated with IL-6 for
up to 24 hours demonstrated no effect on Bcl-2 expres-
sion, although the analysis clearly demonstrated constitu-
tively elevated Bcl-2 expression in Jurkat T-cells as a
positive control (Figure 5A). The expression of Bcl-2 fam-
ily member, Mcl-1, was then measured by immunoblot in
the absence of an antibody that functioned effectively for
intracellular flow cytometry. In contrast to Bcl-2, Mcl-1
expression was significantly increased within 1 hour of IL-
6 treatment, and upregulation persisted for 16 hours. Fur-
ther, treatment with TGF-β1 did not diminish the ability
of IL-6 to induce Mcl-1 expression (Figure 5B). Finally,
considering that the phosphotidyl inositol 3-kinase/Akt
signal pathway has been implicated in the regulation of
Mcl-1 expression [35,36], LCL8664 cells treated with IL-6
for up to 60 minutes were examined by intracellular flow
cytometry to quantify expression of phosphorylated (acti-
vated) Akt. The results demonstrated no effect of IL-6
treatment on Akt activation, although the analysis clearly
demonstrated constitutively activated Akt in Jurkat T-cells,
and its sensitivity to an inhibitor of phosphotidylinositol-
3 phosphate kinase (LY294002), as a positive control
(Figure 5C). Thus, IL-6 appears to exert an anti-apoptotic
effect on LCL8664 cells through the induction of Mcl-1,
although not through Akt or Bcl-2.
As LCL8664 and other SAIDS-NHL-derived cell lines are
useful to the extent that they faithfully model AIDS-NHL,
studies were next performed to establish which subtype(s)
of AIDS-NHL is (are) effectively modeled by LCL8664
with respect to their response to IL-6 and TGF-β1. Three
human AIDS-NHL-derived cell lines representing distinct
histologic subtypes, i.e., 2F7, BCBL-1 and UMCL01-101,
were treated with IL-6, TGF-β1, or a combination of both
Activated (phosphorylated) STAT3 and ERK1/2 in LCL8664 cells treated with IL-6 and/or TGF-β1 Figure 3
Activated (phosphorylated) STAT3 and ERK1/2 in LCL8664 cells treated with IL-6 and/or TGF-β1. LCL8664 cells were treated 
with IL-6 (20 ng/ml), TGF-β1 (1 ng/ml), both, or were untreated for time intervals between 0 – 60 minutes. Phosphorylated 
STAT3 (pSTAT3) and phosphorylated ERK1/2 (pERK1/2) were detected by intracellular flow cytometry.
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cytokines for 0 to 6 days, and growth was measured at reg-
ular intervals by MTT assay (Figure 6). BCBL-1 cell growth
was modestly but significantly stimulated by IL-6, but was
insensitive to treatment with TGF-β1. Since the growth of
BCBL-1 cells was not inhibited by TGF-β1, this cell line
was not further examined. Both 2F7 and UMCL01-101
showed marked sensitivity to TGF-β1-mediated growth
inhibition, but only UMCL01-101 responded to IL-6
when added either alone or in combination with TGF-β1
(Figure 6). The findings suggest that LCL8664 may model
the lymphoma subtype represented by UMCL01-101, and
that LCL8664 and UMCL01-101 may share a similar
molecular phenotype. To test this possibility, the expres-
sion of EBV-encoded oncogenes LMP-1 and EBNA2 was
examined in 2F7 cells and UMCL01-101 cells by immu-
noblot analysis (Figure 7A). The results demonstrated that
2F7 cells, as is characteristic of AIDS-BL [11,37], do not
generally express either LMP-1 or EBNA2. By contrast,
UMCL01-101 cells express both LMP-1 and EBNA2 (Fig-
ure 7A), a pattern consistent with immunoblastic AIDS-
DLBCL [3]. Further, intracellular flow cytometry demon-
strated constitutive expression of Bcl-6 in 2F7 cells but not
in UMCL01-101 (Figure 7B). This pattern of expression of
LMP-1 and Bcl-6 in 2F7 and UMCL01-101 cells is consid-
ered a hallmark for the definition of AIDS-BL and immu-
noblastic AIDS-DLBCL, respectively [3]. Finally, studies
were performed to determine whether IL-6 acts on human
AIDS-NHL cells by STAT3 stimulation as it does in
LCL8664. Consistent with the lack of responsiveness of
2F7 cells to IL-6 (Figure 6), no activation of STAT3 was
detected after IL-6 treatment (Figure 7C). In contrast, the
rapid activation of STAT3 was observed in UMCL01-101
cells within 5 minutes of IL-6 treatment. As was observed
with LCL8664 cells (Figure 3), TGF-β1 treatment alone
had no effect on STAT3 activation in UMCL01-101 cells,
nor did TGF-β1 treatment delay or diminish STAT3 activa-
tion when added together with IL-6 (Figure 7C).
Discussion
The present study was designed to examine the negative
and positive growth regulatory influences of TGF-β1 and
IL-6, respectively, on SAIDS- and AIDS-NHL cells. The
LCL8664 cell line, although widely used as an experimen-
tal model [7,9,31], had not previously been documented
to represent the original tumor mass. The demonstration
by Southern blot analysis of identical immunoglobulin
heavy chain gene rearrangements in the DNA of LCL8664
and the original tumor mass from which the cell line was
derived confirmed their common origin. LCL8664 cells
demonstrated a marked sensitivity to growth inhibition
by TGF-β1 in a dose-dependent manner, an indication
that lymphomas may be subject to significant growth sup-
pressive influences in vivo. An intriguing recent report
showed that IL-6 could counteract the growth inhibitory
influence of TGF-β1 in a cultured hepatoma cell line. IL-6
was shown in that study to rescue cells from TGF-β1-
mediated apoptosis by a mechanism dependent on activa-
tion of multiple anti-apoptotic signaling pathways [29].
Whether IL-6 can rescue B-lymphoid cells from TGF-β1-
mediated growth inhibition had not previously been
Caspase-3 activity in LCL8664 cells treated with IL-6 and/or TGF-β1 Figure 4
Caspase-3 activity in LCL8664 cells treated with IL-6 and/or TGF-β1. LCL8664 cells were treated with IL-6 (20 ng/ml), TGF-β1 
(1 ng/ml), both, or were untreated (untr) for 16 or 24 hours. Parallel samples were treated with the broad caspase inhibitor, 
zVAD-fmk (zVAD) as a negative control. Caspase-3 activity was quantified in whole cell lysates using a colorimetric assay. The 
data are reported as fold-change in caspase-3 activity relative to untreated samples.
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(A). Bcl-2 expression in LCL8664 cells treated with IL-6 Figure 5
(A).Bcl-2 expression in LCL8664 cells treated with IL-6. LCL8664 cells were treated with IL-6 (20 ng/ml), or were untreated 
(untr), for time intervals between 1 – 24 hours. Bcl-2 expression was examined by intracellular flow cytometry. As a positive 
control, Bcl-2 expression in Jurkat cells was detected using the same methodology. (B). Immunoblot analysis of Mcl-1 expres-
sion in LCL8664 cells treated with IL-6 and/or TGF-β1. In the left panel, LCL8664 cells were treated with IL-6 (20 ng/ml) for 
time intervals between 0 – 24 hours. In the right panel, LCL8664 cells were treated with IL-6 (20 ng/ml), TGF-β1 (1 ng/ml), 
both, or were untreated (C) for 4 hours. The expression of β-tubulin was examined as a loading control. (C). Activated (phos-
phorylated) Akt expression in LCL8664 cells treated with IL-6. LCL8664 cells were treated with IL-6 (20 ng/ml), or were 
untreated (untr), for time intervals between 0 – 60 minutes. Phosphorylated Akt (p-Akt) expression was examined by intra-
cellular flow cytometry. As a positive control, p-Akt expression in Jurkat cells was detected using the same methodology, in the 
presence or absence of LY294002 (50 βM).
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reported, although IL-6 is expressed in AIDS-NHL by the
tumor cells themselves or by tumor-infiltrating cells
[11,13,15-17]. Results of the present study showed that
IL-6 stimulates the proliferation of LCL8664 cells, modu-
lates the inhibitory effect of TGF-β1 and significantly res-
cues cell proliferation as compared to TGF-β1 alone.
These findings suggest a mechanism by which growth sup-
pressive influences in the lymphoma environment might
be balanced.
The binding of IL-6 to its receptor initiates both prolifera-
tive and survival pathways in lymphoid malignancies,
particularly through activation of the MAPK and STAT3
pathways, respectively [26,27,38]. IL-6 was shown to acti-
vate the STAT3 pathway in LCL8664 cells even in the pres-
ence of TGF-β1, the downstream effects of which may
include the activation of both proliferation-associated
and anti-apoptotic proteins that could counteract the
growth-inhibitory effects of TGF-β1 [10,39,40]. Indeed,
STAT3 activation has been previously implicated in the
pathogenesis of AIDS-NHL [18], and in many other can-
cers including breast cancer, multiple myeloma, head and
neck cancer, leukemias, lymphomas, lung cancer and
prostate cancer [41-46]. Consistent with the known effect
of IL-6 on the primarily mitogenic Ras/Raf/ERK MAPK sig-
naling pathway [26,28], ERK1/2 was rapidly activated by
IL-6 in LCL8664 cells, although to a lesser extent in the
presence of TGF-β1. These findings suggest that a modest
proliferative effect mediated by IL-6 through the ERK/
MAPK pathway may contribute at least in part to the abil-
ity of IL-6 to rescue cells from TGF-β1-mediated inhibi-
tion. In addition to the potential proliferative influence,
STAT3 activation exerts a survival influence on target cells.
In multiple myeloma, for example, the inhibition of IL-6
receptor signaling through STAT3 was shown to induce
apoptosis, an indication that IL-6-mediated STAT3 activa-
tion contributes to the pathogenesis of multiple myeloma
by increasing the survival potential of tumor cells [41].
Analysis of sub-G1 DNA content and cleaved caspase-3
activity in LCL8664 cells indicated that TGF-β1 mediates
growth inhibition through apoptotic induction, and that
IL-6 treatment modestly but significantly diminishes the
apoptotic effect. IL-6 appears to exert a survival influence
on LCL8664 cells through induction of the Bcl-2 family
member, Mcl-1, although not through Bcl-2 or Akt. Simi-
larly, Mcl-1 has been identified as an essential survival
protein in human myeloma cells [47,48] as well as in lym-
phoid malignancies and in normal lymphoid cells. Resist-
ance to Fas-mediated apoptosis in large granular
lymphocyte (LGL) leukemia has been attributed to STAT3
activation and increased Mcl-1 expression. The STAT3-
mediated resistance to apoptosis of those cells was inde-
pendent of Bcl-2 expression [49]. Further, a study of nor-
mal peripheral blood B-lymphocytes correlated steady
levels of Mcl-1 with cell survival. Cells undergoing apop-
tosis demonstrated decreased Mcl-1 expression while Bcl-
2 expression was unchanged. The application of survival
stimuli such as interleukin-4 blocked the decrease in Mcl-
1 expression [50]. Thus, our findings support a growing
body of evidence implicating Mcl-1 as the critical survival
protein in certain hematopoietic and lymphoid cells as
well as in other cell types. Recent studies demonstrate that
Mcl-1 may act in survival by sequestering Bim, thereby
preventing a Bax-dependent apoptotic cascade mediated
by free Bim, and consequently preserving mitochondrial
membrane potential [51,52].
Analysis of three human AIDS-NHL-derived cell lines was
undertaken to establish which subtype(s) might be faith-
fully modeled by the LCL8664 cell line with respect to the
response to IL-6 and TGF-β1. 2F7 is an EBV-positive B-cell
line established by single cell cloning from biopsy mate-
rial of an AIDS-BL. Verification that 2F7 actually repre-
sents the original tumor clone was performed by Southern
blot analysis to demonstrate identical immunoglobulin
gene rearrangement [53]. BCBL-1 is a KSHV-positive, EBV-
Positive and negative growth regulation of AIDS-NHL cell lines by TGF-β1 and IL-6 Figure 6
Positive and negative growth regulation of AIDS-NHL cell lines by TGF-β1 and IL-6. BCBL-1, UMCL01-101 and 2F7 cell lines 
were cultured with TGF-β1 (1 ng/ml), IL-6 (20 ng/ml), both, or were untreated. Cell viability was quantified at daily intervals 
thereafter using a tetrazolium dye reduction assay.
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(A). Immunoblot analysis of LMP-1 and EBNA2 expression in 2F7 and UMCL01-101 (UMCL) cell lines Figure 7
(A). Immunoblot analysis of LMP-1 and EBNA2 expression in 2F7 and UMCL01-101 (UMCL) cell lines. The expression of β-
tubulin was examined as a loading control. (B). Bcl-6 expression in 2F7 and UMCL01-101 (UMCL) cell lines as examined by 
intracellular flow cytometry. The shaded and open histograms represent analysis with Bcl-6 antibody and isotype control anti-
body, respectively. (C). Activated (phosphorylated) STAT3 in 2F7 and UMCL01-101 cell lines. 2F7 cells were treated with IL-6 
(20 ng/ml), or were untreated, for time intervals between 0 – 60 minutes. UMCL01-101 cells (UMCL) were treated with IL-6 
(20 ng/ml), TGF-β1 (1 ng/ml), both, or were untreated, for time intervals between 0 – 60 minutes. Phosphorylated STAT3 
(pSTAT3) was detected by intracellular flow cytometry.
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negative B-cell line derived from a body cavity-based
AIDS-NHL [54,55]. UMCL01-101 was derived from an
uncharacterized AIDS-NHL and was provided by the AIDS
and Cancer Specimen Resource. The results demonstrated
that AIDS-NHL cells are variably sensitive to TGF-β1-
mediated growth inhibition and to IL-6 stimulation, an
indication that the response to cytokines such as these
may be a distinguishing characteristic of tumor cell phe-
notype. Of the cell lines examined, the response of
UMCL01-101 most closely resembled that of LCL8664 in
that the marked sensitivity to TGF-β1-mediated growth
inhibition was rescued in part by treatment with IL-6. Fur-
ther commonality of molecular phenotype was estab-
lished through the demonstration that UMCL01-101 cells
express EBV-encoded proteins LMP-1 and EBNA2, but do
not express Bcl-6, a pattern definitive of immunoblastic
AIDS-DLBCL [3]. Finally, as in LCL8664 cells, IL-6 was
shown to activate the STAT3 pathway in UMCL01-101
even in the presence of TGF-β1. Thus, like in LCL8664
cells, IL-6 activation of the STAT3 pathway may account
for the partial rescue of TGF-β1-mediated growth inhibi-
tion. Taken together, these studies indicate that UMCL01-
101 likely represents an immunoblastic AIDS-DLBCL,
and that it is effectively modeled by a SAIDS-NHL-derived
cell line also characterized as immunoblastic. Moreover,
the studies indicate that the sensitivity of immunoblastic
AIDS-DLBCL to TGF-β1-mediated growth inhibition may
be overeome through the stimulation of proliferative and
anti-apoptotic signals by IL-6.
Conclusion
Using an immunoblastic SAIDS-NHL cell line shown to
represent the original tumor mass (Figure 1), initial stud-
ies confirmed a previous report [20] that SAIDS-NHL cells
may be sensitive to TGF-β1-mediated growth inhibition
in a dose-dependent manner (Figure 2A). The marked
sensitivity to growth inhibition by TGF-β1 suggested that
a counteracting positive influence may be operative in
SAIDS-NHL. Based on a previous report that IL-6 counter-
acts the growth inhibitory influence of TGF-β1 in a cul-
tured hepatoma cell line [29], the possible role of IL-6 was
examined in the present system. Studies showed that IL-6
rescues LCL8664 cells, at least partially, from TGF-β1-
mediated growth inhibition (Figure 2B), and that STAT3
activation occurs rapidly after IL-6 treatment even in the
presence of TGF-β1 (Figure 3). The rapid activation of
STAT3 signaling pathways may explain the ability of IL-6
to rescue cells from TGF-β1-mediated growth inhibition,
since STAT3 is known to mediate proiliferative and anti-
apoptotic signaling in normal and tumor cells [39,40].
The rapid activation of the ERK1/2 pathway by IL-6, some-
what blunted but not blocked by TGF-β1, indicates that
proliferative stimulation contributes to the rescue of
LCL8664 from TGF-β1-mediated inhibition. Flow cyto-
metric cell cycle analysis and quantitation of caspase-3
activation indicated that TGF-β1 negatively regulates
growth in LCL8664 at least in part by inducing apoptosis
(Figure 4). IL-6 partially rescues LCL8664 cells from TGF-
β1-mediated apoptosis, perhaps through activation of
expression of the Bcl-2 family member, Mcl-1 (Figure 5).
By comparison, human AIDS-NHL cell lines were
observed to vary in their responsiveness to TGF-β1 and to
IL-6. Of cell lines examined representing three different
AIDS-NHL subtypes, only a recently derived, uncharacter-
ized cell line designated UMCL01-101 demonstrated sen-
sitivity to TGF-β1-mediated inhibition and partial rescue
by IL-6 (Figure 6). Analysis of LMP-1 and Bcl-6 expression
indicated that UMCL01-101, like LCL8664, represents
immunoblastic AIDS-DLBCL (Figure 7A, 7B). Further
analysis of the response to IL-6 demonstrated a rapid acti-
vation of STAT3, even in the presence of TGF-β1 (Figure
7C). Taken together, these findings indicate that immuno-
blastic AIDS-DLBCL remains sensitive to TGF-β1-medi-
ated growth inhibition, and that the inhibition may be
overeome through the stimulation of proliferative and
anti-apoptotic signals by IL-6.
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